Drugs / BeiDouGen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05667220 | Dec 2022 → Oct 2023 | type 2 diabetes mellitus | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06587698 | Aug 2024 → Jul 2028 expected | polycystic ovary syndrome | Peking University Third Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beidougen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05667220 ↗ |
| Route | Oral | “Beidougen capsule 60mg Tid orally” NCT05667220 ↗ |